12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AKB-9778: Phase I data

A U.S. Phase I trial in 48 healthy volunteers showed that single ascending-doses of AKB-9778 were well tolerated. Aerpio plans to start a Phase Ib/IIa trial...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >